Sunshine Biopharma Inc
NASDAQ:SBFM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Optomed Oyj
OMXH:OPTOMED
|
FI |
|
Smart City Development Holdings Ltd
HKEX:8268
|
HK |
|
CNH Industrial NV
MIL:CNHI
|
UK |
|
Beijer Ref AB (publ)
STO:BEIJ B
|
SE |
|
B
|
Beingmate Co Ltd
SZSE:002570
|
CN |
|
Hubei Kailong Chemical Group Co Ltd
SZSE:002783
|
CN |
|
P
|
Petronas Chemicals Group Bhd
KLSE:PCHEM
|
MY |
|
M
|
Mahindra CIE Automotive Ltd
NSE:MAHINDCIE
|
IN |
|
T
|
Teleste Oyj
OMXH:TLT1V
|
FI |
|
D
|
Doral Group Renewable Energy Resources Ltd
TASE:DORL
|
IL |
|
Tegma Gestao Logistica SA
BOVESPA:TGMA3
|
BR |
|
Plan Optik AG
XETRA:P4O
|
DE |
|
Xiaomi Corp
HKEX:1810
|
CN |
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
CN |
|
R
|
Royal Century Resources Holdings Ltd
HKEX:8125
|
HK |
|
S
|
State Grid Yingda Co Ltd
SSE:600517
|
CN |
Sunshine Biopharma Inc
Total Liabilities & Equity
Sunshine Biopharma Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sunshine Biopharma Inc
NASDAQ:SBFM
|
Total Liabilities & Equity
$30.1m
|
CAGR 3-Years
1%
|
CAGR 5-Years
96%
|
CAGR 10-Years
46%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Total Liabilities & Equity
CA$84.4m
|
CAGR 3-Years
62%
|
CAGR 5-Years
149%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Total Liabilities & Equity
$751.6m
|
CAGR 3-Years
17%
|
CAGR 5-Years
10%
|
CAGR 10-Years
36%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Total Liabilities & Equity
$633.2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
27%
|
CAGR 10-Years
26%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Total Liabilities & Equity
CA$86.2m
|
CAGR 3-Years
49%
|
CAGR 5-Years
126%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Total Liabilities & Equity
$221.5m
|
CAGR 3-Years
110%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sunshine Biopharma Inc
Glance View
Sunshine Biopharma, Inc. engages in the research, development, and commercialization of oncology and antiviral drugs. The company is headquartered in Pointe-Claire, Quebec and currently employs 3 full-time employees. The company went IPO on 2008-08-15. In addition, the Company is engaged in the development and commercialization of science-based nutritional supplements. The Company’s drug development operations include SBFM-PL4 Anti-Coronavirus Treatment and Adva-27a Anticancer Drug. The firm is engaged in the development of its Anti-Coronavirus compound, SBFM-PL4. The company is advancing the development of two compounds in parallel with its SBFM-PL4. The Company’s drug development activities have focused on the development of a small molecule, Adva-27a for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells, including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells.
See Also
What is Sunshine Biopharma Inc's Total Liabilities & Equity?
Total Liabilities & Equity
30.1m
USD
Based on the financial report for Dec 31, 2025, Sunshine Biopharma Inc's Total Liabilities & Equity amounts to 30.1m USD.
What is Sunshine Biopharma Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
46%
Over the last year, the Total Liabilities & Equity growth was -2%. The average annual Total Liabilities & Equity growth rates for Sunshine Biopharma Inc have been 1% over the past three years , 96% over the past five years , and 46% over the past ten years .
